Malignant Spindle Cell Tumor | No Matrix Production | Diagnosis of Exclusion
- Fibrosarcoma is a malignant spindle cell tumor producing collagen but NO osteoid or chondroid matrix
- Diagnosis of exclusion requiring extensive immunohistochemistry to rule out other spindle cell tumors
- Herringbone pattern of spindle cells in fascicles is classic histological appearance
- Secondary fibrosarcoma arises in Paget's disease (most common), post-radiation, bone infarct, or chronic osteomyelitis
- Treatment is wide surgical resection; chemotherapy role limited compared to osteosarcoma
- “Incidence has decreased as immunohistochemistry improves - many cases reclassified as UPS or other entities
- “Must exclude dedifferentiated osteosarcoma (look for focal osteoid), synovial sarcoma (SS18-SSX fusion), and metastatic carcinoma
- “Post-radiation sarcoma requires latency period of at least 3-5 years and arises in previously irradiated field
- “Prognosis depends on grade, with high-grade tumors having 50-60% 5-year survival and low-grade 80-90%
Fibrosarcoma requires ruling out all other spindle cell tumors. Must exclude: dedifferentiated osteosarcoma (any osteoid present), synovial sarcoma (SS18-SSX fusion), UPS/MFH, leiomyosarcoma, metastatic spindle cell carcinoma. No specific positive markers.
Defining feature: NO osteoid or chondroid matrix. Produces collagen only. Even focal osteoid excludes diagnosis and suggests osteosarcoma. Extensive sampling mandatory to exclude osteoid.
Arises in abnormal bone: Paget's disease (most common secondary cause), post-radiation (3-20 years latency), bone infarct, chronic osteomyelitis, fibrous dysplasia. Secondary tumors have worse prognosis than primary.
Wide surgical resection is mainstay. Chemotherapy less effective than for osteosarcoma (not routinely used). Radiation for positive margins or unresectable. Grade determines prognosis: high-grade 50-60% 5-year survival, low-grade 80-90%.
Overview and Epidemiology
Fibrosarcoma of bone is a rare primary malignant spindle cell tumor characterized by production of collagen but, critically, no osteoid or chondroid matrix. It represents less than 5% of primary bone sarcomas, with incidence decreasing as improved immunohistochemistry allows reclassification to more specific diagnoses such as undifferentiated pleomorphic sarcoma, synovial sarcoma, or dedifferentiated chondrosarcoma.
Fibrosarcoma is clinically important because: (1) it is a diagnosis of exclusion requiring extensive workup to rule out other spindle cell tumors; (2) the incidence has dramatically decreased over past 30 years as immunohistochemistry has improved, suggesting many historical cases were misclassified; (3) secondary fibrosarcoma signals malignant transformation of pre-existing bone pathology; and (4) treatment approach differs from osteosarcoma with limited chemotherapy role.
- Age: Peak 30-50 years (range 10-80 years)
- Sex: No significant gender predilection (1:1 ratio)
- Location: Femur and tibia most common (60%), any bone can be affected
- Incidence: Rare and decreasing with improved diagnostics
- Long bones: Femur (30%), tibia (25%), humerus (15%)
- Axial: Pelvis, mandible, spine (uncommon)
- Location in bone: Metaphyseal most common, can be diaphyseal
- Central vs periosteal: Central (medullary) more common than surface
Primary versus Secondary Fibrosarcoma
- Primary Fibrosarcoma
- None (de novo in normal bone)
- Secondary Fibrosarcoma
- Paget's, radiation, infarct, osteomyelitis
- Primary Fibrosarcoma
- 30-50 years typically
- Secondary Fibrosarcoma
- Older (over 50 years for Paget's, radiation)
- Primary Fibrosarcoma
- Not applicable
- Secondary Fibrosarcoma
- 3-20 years for radiation, variable for Paget's
- Primary Fibrosarcoma
- Grade-dependent, 60% 5-year survival high-grade
- Secondary Fibrosarcoma
- Worse prognosis, 30-40% 5-year survival
- Primary Fibrosarcoma
- De novo
- Secondary Fibrosarcoma
- Paget's disease (1% degeneration rate)
Pathophysiology and Histology
Pathogenesis
Fibrosarcoma arises from primitive mesenchymal cells that differentiate along fibroblastic lineage, producing collagen but failing to produce bone or cartilage matrix. The exact molecular pathogenesis remains incompletely understood, but genetic studies suggest complex karyotypes without consistent chromosomal translocations (unlike synovial sarcoma or Ewing sarcoma).
Fibrosarcoma has no specific positive immunohistochemical markers. Diagnosis requires: (1) demonstration of spindle cell morphology with collagen production; (2) absence of osteoid or chondroid matrix on extensive sampling; (3) negative immunostains for other entities (S100, cytokeratin, muscle markers, CD99, etc.); and (4) absence of specific genetic translocations. Many historical cases have been reclassified as UPS or other specific entities.
Histological Features
- Low-Grade
- Moderate, uniform distribution
- Intermediate-Grade
- Increased, variable
- High-Grade
- High, densely packed cells
- Low-Grade
- Well-organized fascicles
- Intermediate-Grade
- Less organized, focal disruption
- High-Grade
- Disorganized, sheet-like areas
- Low-Grade
- Mild, uniform nuclei
- Intermediate-Grade
- Moderate pleomorphism
- High-Grade
- Marked pleomorphism, variation
- Low-Grade
- Less than 5 per 10 HPF
- Intermediate-Grade
- 5-10 per 10 HPF
- High-Grade
- Greater than 10 per 10 HPF
- Low-Grade
- Abundant, dense
- Intermediate-Grade
- Variable amount
- High-Grade
- Sparse, immature
- Low-Grade
- Absent
- Intermediate-Grade
- Focal (less than 10%)
- High-Grade
- Extensive (over 10%)
- Low-Grade
- 80-90%
- Intermediate-Grade
- 60-70%
- High-Grade
- 50-60%
- Spindle cells: Elongated fibroblasts with tapered nuclei
- Herringbone pattern: Fascicles intersecting at acute angles
- Collagen: Varying amounts of collagen production
- No matrix: Critically, no osteoid or chondroid matrix
- Vascular: Variable vascularity, no specific pattern
- Vimentin: Positive (nonspecific mesenchymal marker)
- S100: Negative (excludes nerve sheath tumor)
- Cytokeratin: Negative (excludes carcinoma, synovial sarcoma)
- Desmin/SMA: Negative (excludes muscle tumors)
- CD99: Negative (excludes Ewing sarcoma)
- MDM2: Negative (excludes dedifferentiated liposarcoma)
Molecular Features
Unlike many sarcomas, fibrosarcoma has no consistent chromosomal translocation. This absence of specific genetic signature contributes to diagnostic challenge. Complex karyotypes are typical but non-specific. Molecular testing is primarily used to exclude other entities:
- SS18-SSX fusion: Absent (excludes synovial sarcoma)
- MDM2 amplification: Absent (excludes dedifferentiated liposarcoma)
- FUS rearrangement: Absent (excludes low-grade fibromyxoid sarcoma)
Enneking (MSTS) Surgical Staging
The topic repeatedly relies on the Enneking system - "Enneking Stage IIB" (Papagelopoulos series and the Paget viva) and the Enneking margin definitions (intralesional / marginal / wide / radical) - but never sets out the staging system itself.
The Enneking / Musculoskeletal Tumor Society (MSTS) surgical staging of a malignant bone or soft-tissue sarcoma combines three axes:
- Grade (G): G1 = low-grade, G2 = high-grade (histological/biological aggressiveness).
- Site (T): T1 = intracompartmental (confined within the bone or compartment of origin), T2 = extracompartmental (breached the cortex/compartment into surrounding tissue).
- Metastasis (M): M0 = none, M1 = regional or distant metastasis.
These combine into stages:
- Stage I (low-grade, M0): IA = G1 T1 M0; IB = G1 T2 M0.
- Stage II (high-grade, M0): IIA = G2 T1 M0; IIB = G2 T2 M0.
- Stage III (any metastasis): any G, any T, M1.
Why it matters here: most fibrosarcomas present as stage IIB - high-grade, with cortical breakthrough into a soft-tissue mass and no metastases - which is exactly the dominant group in the Papagelopoulos series and the reason the standard operation is a wide en-bloc resection. A low-grade, intracompartmental tumour (IA/IB) carries a much better outlook, while any M1 disease (stage III) shifts the goal toward systemic control. This surgical staging is distinct from the AJCC TNM system, but it is the framework orthopaedic examiners expect for bone sarcoma.
Q: How is the Enneking (MSTS) surgical stage determined, and what stage is a typical fibrosarcoma? A: Combine three axes - grade (G1 low / G2 high), compartment (T1 intracompartmental / T2 extracompartmental) and metastasis (M0/M1). Low-grade M0 = stage I (IA T1, IB T2); high-grade M0 = stage II (IIA T1, IIB T2); any metastasis = stage III. Most fibrosarcomas are IIB (high-grade, extracompartmental, no metastasis), which is why wide en-bloc resection is standard.
How the Grade Is Assigned: The FNCLCC System
Grade is called "the single most important prognostic factor" throughout this topic, and the controversies name the FNCLCC and Broders systems - but the body never explains how the grade is actually assigned.
The FNCLCC grade (Fédération Nationale des Centres de Lutte Contre le Cancer) is the standard, reproducible sarcoma grade, built from three scored parameters:
- Tumour differentiation (score 1-3): 1 = closely resembles normal adult mesenchymal tissue (well-differentiated), through to 3 = undifferentiated, embryonal or uncertain-lineage sarcomas.
- Mitotic count (score 1-3): 1 = 0-9, 2 = 10-19, 3 = 20 or more mitoses per 10 high-power fields.
- Tumour necrosis (score 0-2): 0 = none, 1 = under 50%, 2 = 50% or more.
total 2-3 = Grade 1 (low), 4-5 = Grade 2 (intermediate), 6-8 = Grade 3 (high).
the topic's low/intermediate/high table (cellularity, herringbone organisation, atypia, mitoses, necrosis) describes the same features the FNCLCC formalises, and it is usually the mitotic count and necrosis that push a fibrosarcoma into the high-grade group with its 50-60% 5-year survival. The grade then feeds directly into the Enneking stage (G1 versus G2) and the decision whether to consider adjuvant chemotherapy.
FNCLCC was derived largely for soft-tissue sarcoma and applied to bone by extension; interobserver variability in the differentiation score is real; and it performs less well for some translocation-associated sarcomas - which is why grade is combined with, not a substitute for, the full histological and molecular assessment.
Q: How is the FNCLCC grade calculated? A: Sum three parameters - tumour differentiation (1-3), mitotic count (1 = 0-9, 2 = 10-19, 3 = 20 or more per 10 HPF) and necrosis (0 = none, 1 = under 50%, 2 = 50% or more). Total 2-3 = grade 1, 4-5 = grade 2, 6-8 = grade 3. In fibrosarcoma the mitotic count and necrosis usually decide high versus low grade, and grade is the dominant prognostic factor and the G-axis of the Enneking stage.
Clinical Presentation
Symptoms
The presentation of fibrosarcoma is non-specific, similar to other primary bone malignancies. Progressive pain is the most common initial symptom, often present for weeks to months before diagnosis. Unlike benign lesions, pain is typically progressive, not activity-related, and may be present at rest or night.
- Duration: Weeks to months, progressive
- Pattern: Constant, may worsen at night
- Severity: Moderate to severe, progressive
- Relief: Poor response to NSAIDs
- Radiation: May follow nerve distribution if compression
- Pathological fracture: 10-20% present with fracture
- Swelling/mass: Palpable if soft tissue extension
- Limited motion: If near joint
- Systemic: Usually absent (no fever, weight loss)
- Neurological: Rare unless neural compression
Physical Examination
Systematic Examination Approach
- Swelling: Visible if large soft tissue component
- Skin changes: Usually normal, may see venous prominence
- Gait: Antalgic gait if lower limb affected
- Deformity: May see angular deformity if pathological fracture
- Tenderness: Localized bony tenderness over lesion
- Mass: Firm, fixed to bone if large or cortical breakthrough
- Temperature: Normal (not warm like infection)
- Neurovascular: Assess distal pulses, sensation, motor function
- ROM: May be limited by pain if juxta-articular
- Strength: Reduced if muscle involvement or pain
- Stability: Assess for pathological fracture
- Lymph nodes: Usually not enlarged (bone sarcomas rarely lymphatic spread)
- Distant sites: Examine chest for metastases (rare on exam)
Immediate evaluation needed if:
- Progressive neurological deficit suggesting spinal cord or nerve compression
- Acute onset pain with deformity suggesting pathological fracture
- Rapid increase in swelling suggesting aggressive growth or hemorrhage
- Systemic symptoms (fever, weight loss) suggesting infection or disseminated disease
Secondary Fibrosarcoma Presentation
- Clinical Clue
- Known Paget's with sudden pain increase
- Typical Presentation
- Elderly patient, alkaline phosphatase elevated, rapid progression
- Clinical Clue
- Prior radiation therapy 3-20 years ago
- Typical Presentation
- Lesion arises in previously irradiated field, latency period essential
- Clinical Clue
- Known chronic infarct with new symptoms
- Typical Presentation
- Sickle cell disease, steroid use, expanding infarct on imaging
- Clinical Clue
- Long-standing draining sinus, new mass
- Typical Presentation
- Years of infection, sudden change in character, biopsy needed
Investigations and Imaging
Plain Radiography
Plain X-rays show a destructive lytic lesion with geographic, moth-eaten, or permeative pattern depending on grade. Higher grade tumors demonstrate more aggressive radiographic features. Critically, there is no matrix calcification or ossification (this would suggest osteosarcoma or chondrosarcoma).
- Pattern: Lytic, destructive
- Margin: Geographic (low-grade) to permeative (high-grade)
- Matrix: None (no calcification or ossification)
- Periosteal reaction: Variable, may show Codman triangle in aggressive cases
- Soft tissue mass: Often visible if cortical breakthrough
- Incidence: 10-20% present with fracture
- Pattern: Transverse or oblique through lesion
- Displacement: Variable
- Management impact: May require staged procedure (stabilization then resection)
- Prognosis: Unclear if fracture worsens prognosis
Computed Tomography (CT)
CT provides superior bone detail and is essential for surgical planning. CT chest is mandatory for staging to detect pulmonary metastases (lung is most common metastatic site for bone sarcomas).
CT Protocol for Fibrosarcoma
- Thin slice acquisition (1mm or less)
- Bone and soft tissue windows
- Multiplanar reconstruction
- Assess cortical destruction, soft tissue extent
- Identify neurovascular structures at risk
- Detect pulmonary metastases
- Nodules greater than 5mm suspicious
- Baseline for follow-up comparison
- Alternative: PET-CT for whole-body staging
- Medullary destruction pattern
- Cortical breakthrough location and extent
- Soft tissue mass size and margins
- Relationship to neurovascular bundle
- Skip lesions (rare but important to detect)
Magnetic Resonance Imaging (MRI)
MRI is the imaging modality of choice for local staging, surgical planning, and assessing intramedullary extent. Superior soft tissue contrast allows assessment of muscle, nerve, and vascular involvement.
- Signal Intensity
- Low to intermediate signal (isointense to muscle)
- Clinical Significance
- Defines anatomical extent, marrow involvement
- Signal Intensity
- High signal (heterogeneous)
- Clinical Significance
- Soft tissue extent, edema pattern
- Signal Intensity
- Heterogeneous enhancement
- Clinical Significance
- Viable tumor (enhances), necrosis (does not enhance)
- Signal Intensity
- High signal
- Clinical Significance
- Sensitive for marrow edema, extent beyond gross tumor
- Signal Intensity
- High signal in tumor
- Clinical Significance
- Differentiates edema from tumor, soft tissue extent
Biopsy
Histological confirmation is mandatory before definitive treatment. Biopsy should be performed by the treating surgeon or in coordination with the surgical team to ensure proper trajectory that can be excised during definitive surgery.
Essential biopsy considerations:
- Biopsy performed by or coordinated with treating surgeon
- Core needle biopsy preferred (less contamination than open biopsy)
- Trajectory must be excisable during definitive resection (longitudinal incision in extremity)
- Avoid transarticular or transneural trajectory
- Multiple cores needed (3-5 samples minimum)
- Avoid hematoma (use meticulous hemostasis, avoid drain if possible)
- Send fresh tissue for molecular studies if available
- Approach: CT or fluoroscopy-guided core needle (11-14 gauge)
- Samples: Multiple cores (3-5 minimum) from different areas
- Trajectory: Longitudinal in extremity, excisable during definitive surgery
- Fresh tissue: Send for molecular studies, culture if infection suspected
- Hemostasis: Critical to avoid hematoma and contamination
- Expert review: Musculoskeletal pathologist mandatory
- Extensive sampling: Multiple sections to exclude osteoid
- Immunohistochemistry: Panel to exclude other spindle cell tumors
- Molecular: Consider if diagnosis uncertain (exclude fusions)
- Grading: Low, intermediate, or high-grade determination
Staging Workup
- Purpose
- Initial assessment, surgical planning
- Findings
- Lytic destructive lesion, no matrix calcification
- Purpose
- Soft tissue extent, surgical planning
- Findings
- Intramedullary and extraosseous extent, neurovascular relationship
- Purpose
- Detect pulmonary metastases
- Findings
- Lung nodules if metastatic
- Purpose
- Detect skip lesions, bone metastases
- Findings
- PET-CT or bone scan
- Purpose
- Histological diagnosis and grading
- Findings
- Spindle cell tumor, no osteoid, immunophenotype
- Purpose
- Baseline, exclude other pathology
- Findings
- Alkaline phosphatase (usually normal unless Paget's), LDH
Differential Diagnosis
- Histology
- Herringbone spindle cells, no osteoid
- Immunohistochemistry
- Vimentin+, all others negative
- Molecular
- No specific translocation
- Key Distinguishing Feature
- Diagnosis of exclusion
- Histology
- Spindle cells WITH osteoid (even focal)
- Immunohistochemistry
- Variable
- Molecular
- Complex karyotype
- Key Distinguishing Feature
- ANY osteoid production excludes fibrosarcoma
- Histology
- Monophasic (spindle) or biphasic
- Immunohistochemistry
- Cytokeratin+, EMA+, CD99+
- Molecular
- SS18-SSX fusion
- Key Distinguishing Feature
- Cytokeratin positivity, fusion gene
- Histology
- Pleomorphic, storiform pattern
- Immunohistochemistry
- Vimentin+, variable others
- Molecular
- Complex karyotype
- Key Distinguishing Feature
- Storiform pattern, marked pleomorphism
- Histology
- Spindle cells with cigar-shaped nuclei
- Immunohistochemistry
- SMA+, desmin+, h-caldesmon+
- Molecular
- Variable
- Key Distinguishing Feature
- Smooth muscle markers positive
- Histology
- Spindle cell variant (sarcomatoid)
- Immunohistochemistry
- Cytokeratin+, epithelial markers+
- Molecular
- Primary site specific
- Key Distinguishing Feature
- Epithelial markers, known primary
Key distinguishing features:
Fibrosarcoma: NO osteoid or chondroid matrix on extensive sampling, spindle cells produce collagen only, herringbone pattern, diagnosis of exclusion after immunohistochemistry panel.
Osteosarcoma: Production of osteoid by definition (even focal osteoid), malignant osteoblasts, more pleomorphic, alkaline phosphatase often elevated.
Exam answer: "The critical difference is osteoid production. Even focal osteoid on extensive sampling excludes fibrosarcoma and indicates osteosarcoma. Fibrosarcoma produces collagen but no bone or cartilage matrix. Thorough sampling of multiple areas is essential as osteosarcoma can have dedifferentiated areas mimicking fibrosarcoma."
Management Algorithm
Treatment Algorithm
Primary Fibrosarcoma Surgical Management
Goal: Complete tumor resection with wide oncological margins while preserving limb function when feasible.
Surgical Approach for Primary Fibrosarcoma
- Multidisciplinary tumor board discussion (surgeon, radiologist, pathologist, oncologist)
- Review all imaging (MRI for extent, CT for bone detail)
- Plan resection margins (1-2cm or fascial barrier)
- Plan reconstruction (allograft, endoprosthesis, autograft)
- Patient counseling: risks, alternatives, functional outcomes
- En bloc resection with wide margins (1-2cm in all directions)
- Include biopsy tract in specimen
- Preserve neurovascular structures if oncologically safe
- Send specimen margins for frozen section
- Reconstruct if structural defect created
- Endoprosthesis: Megaprosthetic replacement (most common for long bones)
- Allograft: Intercalary or osteoarticular allograft
- Allograft-prosthetic composite: Combine advantages
- Autograft: Vascularized fibular graft (less common)
- Arthrodesis: If joint sacrifice necessary and endoprosthesis not suitable
Surgical margin definitions (Enneking):
- Intralesional: Tumor violated, gross disease left behind (not acceptable for fibrosarcoma)
- Marginal: Through reactive zone, microscopic disease likely (inadequate, high recurrence)
- Wide: Through normal tissue, may have skip lesions if insufficient margin (goal for fibrosarcoma)
- Radical: Entire compartment removed (rarely necessary for bone sarcomas)
Target for fibrosarcoma: Wide margins (1-2cm or anatomical barrier such as fascia, joint capsule, periosteum of uninvolved bone).
- Advantages
- Immediate stability, early mobilization, predictable
- Disadvantages
- Infection risk, loosening, limited lifespan
- Best Use
- Older patients, large defects, poor bone quality
- Advantages
- Biological, potential for remodeling, no foreign material
- Disadvantages
- Fracture risk, nonunion, disease transmission risk, slow incorporation
- Best Use
- Young patients, moderate defects
- Advantages
- Combines stability with biology, soft tissue attachment
- Disadvantages
- Both allograft and prosthesis complications possible
- Best Use
- Juxta-articular resections, need for soft tissue reattachment
- Advantages
- Biological, living bone, remodels, low infection
- Disadvantages
- Donor site morbidity, stress fracture, technically demanding, slow hypertrophy
- Best Use
- Young patients, smaller defects, high-demand patients
Complications and Outcomes
Complications
- Incidence
- 10-30% depending on grade and margins
- Risk Factors
- Inadequate margins, high-grade, contaminated biopsy tract
- Management
- Re-excision with wider margins, consider radiation
- Incidence
- 30-40% for high-grade
- Risk Factors
- High-grade, tumor size over 8cm, elevated LDH
- Management
- Pulmonary metastasectomy if resectable, chemotherapy
- Incidence
- 5-15%
- Risk Factors
- Megaprosthetic reconstruction, long operative time, poor soft tissue coverage
- Management
- Debridement, antibiotics, may require prosthesis removal
- Incidence
- 10-20%
- Risk Factors
- Allograft reconstruction, delayed union, stress riser
- Management
- Protected weight-bearing, may require revision
- Incidence
- 2-5%
- Risk Factors
- Tumor proximity to vessels/nerves, extensive dissection
- Management
- Immediate repair if recognized, consultation
- Incidence
- Variable
- Risk Factors
- Muscle resection, nerve sacrifice, stiffness
- Management
- Rehabilitation, physiotherapy, functional bracing
Prognosis and Survival
- Low-grade histology: Well-differentiated tumor
- Wide surgical margins: Greater than 1cm in all planes
- Small size: Less than 5cm diameter
- Primary (not secondary): De novo arising in normal bone
- Distal location: Better salvage options if recurrence
- No metastases: At presentation or during treatment
- High-grade histology: Poorly differentiated, high mitotic rate, necrosis
- Marginal or inadequate margins: Less than 1cm or positive
- Large size: Greater than 8cm
- Secondary fibrosarcoma: Arising in Paget's, radiation field, infarct
- Axial location: Pelvis, spine (difficult wide margins)
- Metastatic disease: At presentation or early development
Post-treatment surveillance for fibrosarcoma:
- First 2 years: Clinical examination and local imaging (X-ray or MRI) every 3 months, CT chest every 3 months
- Years 3-5: Clinical and local imaging every 4-6 months, CT chest every 6 months
- After 5 years: Annual follow-up, CT chest annually
- Local recurrence: 80% occur within first 2 years, 90% within 5 years
- Metastases: Majority within first 3 years, lung most common site
Surveillance intensity should be higher for high-grade tumors and lower for low-grade.
Guidelines, Registries & Global Practice
Global Epidemiology
Fibrosarcoma of bone accounts for less than 5% of primary bone sarcomas worldwide, and reported incidence has fallen markedly over recent decades as immunohistochemistry and molecular testing reclassify many historical cases as undifferentiated pleomorphic sarcoma, leiomyosarcoma or dedifferentiated chondrosarcoma. It is best regarded as one of the rare primary malignant bone sarcomas (RPMBS), which collectively make up 5-10% of high-grade bone tumours (EURO-B.O.S.S.). Peak age is 30-50 years for primary disease, shifting older for secondary tumours arising in Paget disease or irradiated bone.
Society Guidance, Side by Side
- Diagnostic stance
- Fibrosarcoma is a diagnosis of exclusion after IHC/molecular workup; many spindle cell sarcomas of bone now coded as 'undifferentiated/spindle cell sarcoma NOS'
- Treatment emphasis
- Grade-based risk stratification; defines the entity rather than therapy
- Diagnostic stance
- Mandatory expert sarcoma pathology review; central reference panels encouraged
- Treatment emphasis
- Wide resection at a reference centre; perioperative chemo for high-grade per RPMBS data
- Diagnostic stance
- Referral to a designated bone sarcoma diagnostic and treatment centre (network model)
- Treatment emphasis
- MDT-directed wide excision and limb salvage; chemo decided case-by-case at the network MDT
- Diagnostic stance
- Treats non-osteosarcoma high-grade spindle/pleomorphic bone sarcoma broadly on the osteosarcoma pathway
- Treatment emphasis
- Wide resection; consider osteosarcoma-type chemotherapy for high-grade disease
- Diagnostic stance
- Pre-treatment biopsy along an excisable tract, planned with the resecting surgeon
- Treatment emphasis
- Reconstruction (endoprosthesis, allograft, APC) and stable fixation after wide resection
Registries and Evidence Networks
- Reference-centre registries (e.g. Rizzoli/EMSOS in Europe, Mayo and Memorial Sloan-Kettering historical series) supply almost all outcome data, because population numbers are tiny at any single unit.
- Cooperative trial groups (EURO-B.O.S.S., COSS, Euro-EWING networks) pool rare bone sarcomas to generate prospective chemotherapy evidence — the basis for offering osteosarcoma-type regimens in fit high-grade patients.
- There is no implant survivorship registry endpoint specific to fibrosarcoma; reconstruction outcomes are extrapolated from limb-salvage endoprosthesis and allograft series.
High- versus Limited-Resource Practice
- Specialist MSK pathology with full IHC and molecular panels
- MRI, CT chest and PET-CT staging routinely available
- Limb salvage with custom endoprostheses or allografts
- Multidisciplinary tumour board and prospective trial enrolment
- Restricted IHC may force a descriptive "spindle cell sarcoma" diagnosis
- Late presentation with large tumours and pathological fracture is common
- Amputation more often the realistic margin-achieving option than complex reconstruction
- Chemotherapy access and supportive-care capacity constrain osteosarcoma-type regimens
Controversies and Areas of Uncertainty
With modern immunohistochemistry and molecular testing, many tumours formerly called fibrosarcoma are reclassified as UPS, leiomyosarcoma or dedifferentiated chondrosarcoma. The WHO trend is toward "undifferentiated/spindle cell sarcoma NOS". Whether true fibrosarcoma is a distinct biological entity or a diagnostic residuum remains debated.
Historically considered chemo-resistant, but EURO-B.O.S.S. showed osteosarcoma-type chemotherapy gives survival comparable to age-matched osteosarcoma in high-grade non-osteosarcoma bone sarcomas. There is still no randomised trial proving a survival benefit specifically for fibrosarcoma, and toxicity is significant.
Several grading schemes exist (FNCLCC, three-tier and older Broders-type systems). Interobserver variability is real, yet grade is the single most important prognostic factor. The "right" threshold for calling a tumour high-grade and escalating treatment is not standardised.
The exact millimetre margin that constitutes "wide" and the value of adjuvant radiotherapy for close or positive margins are extrapolated from soft-tissue sarcoma and mixed bone-sarcoma data rather than fibrosarcoma-specific randomised evidence.
MCQ Practice Points
Q: What is the critical histological feature that distinguishes fibrosarcoma from osteosarcoma? A: Absence of osteoid or chondroid matrix production. Fibrosarcoma produces collagen only. Even focal osteoid on extensive sampling excludes fibrosarcoma and indicates osteosarcoma (or dedifferentiated osteosarcoma). This is why thorough sampling of multiple tumor areas is essential.
Q: Why is fibrosarcoma considered a diagnosis of exclusion? A: Fibrosarcoma has no specific positive immunohistochemical markers or genetic translocations. Diagnosis requires: (1) spindle cell morphology with herringbone pattern, (2) collagen production without osteoid/chondroid, (3) negative immunostains for other entities (S100, cytokeratin, muscle markers, CD99, MDM2), (4) absence of specific fusions (SS18-SSX, FUS). Many historical fibrosarcomas have been reclassified as UPS or other specific entities with modern diagnostics.
Q: What are the causes of secondary fibrosarcoma of bone, and which is most common? A: PRIC mnemonic: (1) Paget's disease (most common secondary cause, 1% degeneration rate), (2) Radiation therapy (3-20 year latency), (3) Infarct (chronic bone infarct), (4) Chronic osteomyelitis (very rare, also fibrous dysplasia). Secondary fibrosarcomas have significantly worse prognosis (20-40% 5-year survival) than primary fibrosarcoma (60-90% depending on grade).
Q: What is the role of chemotherapy in fibrosarcoma of bone, and how does it differ from osteosarcoma? A: Unlike osteosarcoma where neoadjuvant and adjuvant chemotherapy is standard, fibrosarcoma has no proven benefit from chemotherapy. Fibrosarcoma is less chemosensitive than osteosarcoma. Some centers may use chemotherapy for high-grade tumors based on soft tissue sarcoma protocols (doxorubicin, ifosfamide), but evidence is limited and not routine standard of care. Decision should be individualized at multidisciplinary tumor board.
Q: What are the 5-year survival rates for fibrosarcoma based on grade and primary versus secondary? A: Grade-dependent survival: Low-grade 80-90%, high-grade 50-60%. Secondary fibrosarcoma (Paget's, post-radiation, infarct) has significantly worse prognosis at 20-40% 5-year survival. Post-radiation sarcoma specifically has approximately 20-30% 5-year survival. Grade is the most important prognostic factor for primary fibrosarcoma.
Q: What are the diagnostic criteria for post-radiation sarcoma (Cahan criteria)? A: Modified Cahan criteria: (1) Tumor arises in previously irradiated field, (2) Latency period of at least 3-5 years after radiation, (3) Histologically different from original tumor (if radiation for malignancy), (4) Histologically confirmed sarcoma. These criteria distinguish radiation-induced sarcoma from recurrent original tumor or coincidental new tumor.
At a Glance
Fibrosarcoma of bone is a rare malignant spindle cell tumor comprising less than 5% of primary bone sarcomas, with peak incidence in patients aged 30-50 years. The defining histological feature is production of collagen in a classic herringbone pattern without any osteoid or chondroid matrix—even focal osteoid production excludes the diagnosis and suggests osteosarcoma. Fibrosarcoma is truly a diagnosis of exclusion, requiring extensive immunohistochemistry to rule out dedifferentiated osteosarcoma, synovial sarcoma (SS18-SSX fusion), undifferentiated pleomorphic sarcoma (UPS), and metastatic spindle cell carcinoma. Secondary fibrosarcoma arises from pre-existing conditions (Paget's disease most commonly, post-radiation with 3-20 year latency, bone infarct, chronic osteomyelitis) and carries worse prognosis than primary tumors. Treatment is wide surgical resection; chemotherapy is less effective than for osteosarcoma and not routinely used. Prognosis depends on grade: high-grade 50-60% 5-year survival, low-grade 80-90%.
PRICSecondary Fibrosarcoma Causes
Hook:PRIC causes: Paget's most common, Radiation with latency, Infarct chronic, Chronic infection!
FOCUSSpindle Cell Bone Tumors to Exclude
Hook:FOCUS on exclusion: Fibrosarcoma, Osteosarcoma, Carcinoma, UPS, Synovial sarcoma!
CHAMPFibrosarcoma Grading Features
Hook:CHAMP features determine grade: Cellularity, Herringbone, Atypia, Mitoses, Pattern!
Exam Viva Scenarios
Practise clinical reasoning and management decisions out loud
“A 40-year-old male presents with 3 months of progressive thigh pain. X-ray shows a 6cm lytic destructive lesion in the mid-femoral diaphysis with no matrix calcification. CT-guided biopsy reports spindle cells in herringbone pattern with no osteoid production. Immunohistochemistry shows vimentin positive, all other stains negative. How would you manage this patient?”
“A 72-year-old female with known polyostotic Paget's disease presents with sudden increase in pain in her proximal femur over 2 months. She has had Paget's for 20 years managed with bisphosphonates. X-ray shows a destructive lytic lesion in the proximal femur with cortical breakthrough in an area previously affected by Paget's. Alkaline phosphatase is markedly elevated at 950 (previously 400). What is your differential diagnosis and management approach?”
“A 55-year-old male was treated with radiation therapy 12 years ago for Ewing sarcoma of the proximal tibia (limb salvage with resection and allograft). He now presents with progressive pain and a new destructive lesion at the proximal tibia in the previously irradiated field. Biopsy confirms high-grade fibrosarcoma. CT chest shows no metastases. How would you counsel and manage this patient?”
Key Features
- Malignant spindle cell tumor producing collagen, NO osteoid or chondroid matrix
- Less than 5% of primary bone sarcomas, incidence decreasing (reclassification)
- Peak age 30-50 years, equal gender distribution
- Femur and tibia most common (60%), metaphyseal predominant
- Diagnosis of exclusion - no specific positive markers or translocations
Histology and Diagnosis
- Herringbone pattern of spindle cells in fascicles
- Collagen production, NO osteoid (critical - excludes osteosarcoma)
- Graded by cellularity, atypia, mitotic rate, necrosis (low/intermediate/high)
- Vimentin positive, all other immunostains negative (S100, cytokeratin, desmin, CD99 all negative)
- Must exclude: osteosarcoma (osteoid), synovial sarcoma (SS18-SSX), UPS, carcinoma
Secondary Fibrosarcoma (PRIC)
- Paget's disease - most common secondary cause, 1% degeneration rate
- Radiation - 3-20 year latency, Cahan criteria (field, latency over 3 years, different histology)
- Infarct - chronic bone infarct, sickle cell or steroid history
- Chronic osteomyelitis - very rare, also fibrous dysplasia
- Secondary fibrosarcoma prognosis: 20-40% 5-year survival (vs 60-90% primary)
Imaging and Staging
- X-ray: Lytic destructive lesion, NO matrix calcification/ossification
- MRI: Soft tissue extent, neurovascular relationship (T1 low, T2 high, heterogeneous enhancement)
- CT chest: Mandatory for staging (lung most common metastatic site)
- Biopsy: Core needle preferred, excisable trajectory, multiple samples to exclude osteoid
- PET-CT: Whole-body staging, assess for skip lesions
Treatment
- Wide surgical resection - primary treatment (1-2cm margins or fascial barrier)
- Reconstruction: Endoprosthesis, allograft, allograft-prosthetic composite, vascularized fibula
- Chemotherapy: Limited role (NOT standard like osteosarcoma), may consider for high-grade
- Radiation: Positive margins, unresectable, dose 60-66 Gy
- Amputation: If wide margins not achievable or unresectable with limb salvage
Prognosis and Surveillance
- Low-grade: 80-90% 5-year survival
- High-grade: 50-60% 5-year survival
- Secondary (Paget's, radiation, infarct): 20-40% 5-year survival
- Grade most important prognostic factor, also size, margins, primary vs secondary
- Surveillance: Every 3 months for 2 years (clinical, local imaging, CT chest), then every 6 months to 5 years
Differential Diagnosis (Spindle Cell Tumors)
- Osteosarcoma (dedifferentiated) - ANY osteoid production excludes fibrosarcoma
- Synovial sarcoma - Cytokeratin+, EMA+, SS18-SSX fusion
- UPS (MFH) - Storiform pattern, marked pleomorphism
- Leiomyosarcoma - SMA+, desmin+, h-caldesmon+ (smooth muscle markers)
- Metastatic carcinoma - Cytokeratin+, epithelial markers, known primary
Evidence Base and Key Studies
Primary Fibrosarcoma of Bone: A Clinicopathologic Study of 130 Patients
- Classic series of 130 primary fibrosarcoma cases (Memorial Sloan-Kettering, 1918-1973); 89 medullary, 41 periosteal
- Mean age 38 years (range 4-83), near-equal sex distribution, femur the most common site
- Overall 5-year survival 34% (medullary 27%, periosteal 52%); 10-year survival 28%
- Periosteal and low-grade lesions fared substantially better than central high-grade tumors
- Distinguished fibrosarcoma from osteosarcoma, whose 5-year survival was then only ~17%
Primary Fibrosarcoma of Bone: Outcome After Primary Surgical Treatment
- 92 patients with primary fibrosarcoma of bone treated at Mayo Clinic (1910-1995); mean age 38 years
- Femur (28), tibia (21) and pelvis (14) the commonest sites; 66% were Enneking stage IIB
- Overall probability of survival was only 33.4% at 5 years after surgery
- Local recurrence in 15% of patients; metastases developed in 68% of stage I-II patients (median 9 months)
- Independent adverse prognostic factors: age over 40 years, axial location, and high grade (grade 3-4)
Post-Radiation Sarcomas: Clinical Outcome of 52 Patients
- 52 post-radiation sarcomas (45 bone, 7 soft tissue) treated at Rizzoli 1985-2011
- Risk of post-radiation sarcoma 0.06% at a mean latency of 15 years (range 3-50 years)
- Commonest histologies osteosarcoma, then MFH/UPS and fibrosarcoma; all were high grade
- Survival 51% at 2 years and 45% at 5 years; sarcoma type was the only significant predictor
- Wide surgical resection is the only treatment with curative potential as re-irradiation is constrained
Sarcomas Arising in Paget Disease of Bone: A Clinicopathologic Analysis of 70 Cases
- 70 sarcomas arising in Paget disease; predominance in older men (mean age 66) and the axial skeleton, especially pelvis
- Most tumors were osteosarcoma (88%); all were high grade
- 5-year survival just 10%, confirming a dismal prognosis for Paget sarcoma
- No significant correlation between number of involved bones or disease duration and malignant transformation
- Poor outcome was unrelated to site or stage at presentation
Outcome of Rare Primary Malignant Bone Sarcoma Treated With Multimodal Therapy (EURO-B.O.S.S.)
- Prospective European study of 113 patients aged 41-65 with high-grade spindle cell, pleomorphic or vascular bone sarcoma (88 UPS, 20 leiomyosarcoma, 3 fibrosarcoma, 2 angiosarcoma)
- Treated with an osteosarcoma-type regimen (doxorubicin, ifosfamide, cisplatin, with methotrexate for poor responders)
- 5-year overall survival 68.4% for localized disease; better with complete surgical remission and extremity location
- Outcomes were similar to age-matched high-grade osteosarcoma treated on the same protocol
- Substantial toxicity: grade III-IV haematologic toxicity in 81%